INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY **EXAMINATION REPORT**

(PCT Rule 71.1)

Date of Mailing

(day/month/year)

26 OCT 2001

Applicant's or agent's file reference

International application No.

PCT/US00/00583

To: JANE MASSEY LICATA LICATA & TYRRELL 66 E. MAIN STREET MARLTON NJ 08053

Docket System

Status Report

Dacket Book M= 3/9/02

RTSP-0048

IMPORTANT NOTIFICATION

International filing date (day/month/year)

10 JANUARY 2000

Priority Date (day/month/year)

09 SEPTEMBER 1999

Applicant

From the

ISIS PHARMACEUTICALS, INC.

- The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

REMINDER 4.

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume Π of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US

Commissioner of Patents and Trademarks

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

(703) 308-0196

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference RTSP-0048	FOR FURTHER ACTION	Prelimina	
International application No.	International filing date (day/n	PCT/IPEA ionth/year)	Priority date (day/month/year)
PCT/US00/00588	10 JANUARY 2000		09 SEPTEMBER 1999
International Patent Classification (IPC Please See Supplemental Sheet.) or national classification and IP	c	
Applicant ISIS PHARMACEUTICALS, INC.			
Examining Authority and is 2. This REPORT consists of a This report is also accombeen amended and are the	s transmitted to the applicant a total ofsheets. apanied by ANNEXES, i.e., sheet he basis for this report and/or she ion 607 of the Administrative In	according to s of the descrets containing	ription, claims and/or drawings which have trectifications made before this Authority.
3. This report contains indication	_	ms:	
I X Basis of the repo	rt		
II Priority			•
III Non-establishme	nt of report with regard to nov	elty, inventi	ve step or industrial applicability
IV Lack of unity of	invention		
V X Reasoned statemen citations and expla	t under Article 35(2) with regar nations supporting such statemen	d to novelty, at	inventive step or industrial applicability;
VI Certain documents	cited		
VII Certain defects in t	he international application		
VIII Certain observation	s on the international applicatio	n	
			
Date of submission of the demand	Date o	f completion	of this report
05 APRIL 2001	01	OCTOBER 2	001
Name and mailing address of the IPEA	11 //	ed officer	Rudges /
Commissioner of Patents and Tradem Box PCT Washington, D.C. 20231	KA	REN LACOL	PRCIERE
Facsimile No. (703) 305-3230	Teleph	one No. (70	08) 308-0196

International application No.

I. B	asis of the re	eport				
1. Witt	regard to the	elements of the interr	national applica	tion:*	,	
х	-	onal application a				
=	the descript	• •				
X	•				•	, as originally filed
	pages					, filed with the demand
	pages					, med with the demand
	pages			, inca with the i		
[x]	the claims:					
شا	pages	82 and 83				, as originally filed
	pages	NONE				atement) under Article 19
	pages	NONE				, filed with the demand
	pages	NONE	, filed v	with the letter of		
\mathbf{x}	the drawing					
	pages					, as originally filed
	pages					, filed with the demand
	pages	NONE		$_{\scriptscriptstyle -}$, filed with the let	iter of	
_						
X		e listing part of the				11 61 1
	pages	1-12				, as originally filed
	pages	NONE		C1 1 . '41 41 1.4		, filed with the demand
	pages	NONE		_ , filed with the let	tter of	
	the language	e of publication of	the internati	the purposes of inter	der Rule 48.3(b)).	
L	the language or 55.3).	of the translation has	mished for the	purposes of internation	nal preliminary exam	nination (under Rules 55.2 and/
	_	•		d sequence disclosed basis of the sequence		application, the international
\mathbf{x}	contained in	the international	application is	n printed form.		
			• •	ation in computer rea	idable form	
	_	bsequently to this				
님			•	computer readable f	orm.	
님		•				yond the disclosure in the
	international	application as filed	l has been fur	mished.		
	The statemen been furnishe		n recorded in	computer readable for	n is identical to the	writen sequence listing has
4. X	The amenda	ments have resulte	d in the canc	ellation of:		
	X the de	escription, pages	NONE			
		aims, Nos.	NONE			
		awings, sheets/fig	NONE			
5.	This report h	as been drawn as if	(some of) the	amendments had not be	en made, since they	have been considered to go
	beyond the	disclosure as filed, as	s indicated in t	he Supplemental Box (Rule 70.2(c)).**	
in t	lacement sheets his report as '70.17).	s which have been fur "originally filed" and	nished to the r d are not ann	eceiving Office in respon exed to this report sind	nse to an invitation w ce they do not conta	nder Article 14 are referred to in amendments (Rules 70.16
		sheet containing suc	ch amendment	s must be referred to t	under item 1 and an	nexed to this report.

International application No.

statement			
Novelty (N)	Claims	3-20	
• . ,	Claims	1 and 2	N
Inventive Step (IS)	Claims	3, 4, and 16-20	3
22.024.0 Sup (20)	Claims	1, 2, and 5-15	N
Industrial Applicability (IA)	Claims	1-20	Y
	Claims	NONE	P
preceding paragraph and further in view of 1998, pages 69-76). The instant invention	n comprises variou	s chemical modifications to antisense	oligonucleotides targeted
	on comprises variou targeted to XIAP for the various best out in PCT Ar otides recited in class	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o
1998, pages 69-76). The instant invention XIAP. WO 98/35693 disclose antisense oligonucleotides which one would use foligonucleotides. Claims 3, 4, and 16-20 meet the criteria suggest the specific antisense oligonucleotides disease with antisense oligonucleotides.	on comprises variou targeted to XIAP for the various ber set out in PCT Ar otides recited in classed to	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o
1998, pages 69-76). The instant invention XIAP. WO 96/35693 disclose antisense oligonucleotides which one would use it oligonucleotides. Claims 3, 4, and 16-20 meet the criteria suggest the specific antisense oligonucleo	on comprises variou targeted to XIAP for the various ber set out in PCT Ar otides recited in classed to	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o
1998, pages 69-76). The instant invention XIAP. WO 98/35693 disclose antisense oligonucleotides which one would use the oligonucleotides. Claims 3, 4, and 16-20 meet the criteria suggest the specific antisense oligonucleotreating disease with antisense	on comprises variou targeted to XIAP for the various ber set out in PCT Ar otides recited in classed to	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o
1998, pages 69-76). The instant invention XIAP. WO 98/35693 disclose antisense oligonucleotides which one would use the oligonucleotides. Claims 3, 4, and 16-20 meet the criteria suggest the specific antisense oligonucleotreating disease with antisense	on comprises variou targeted to XIAP for the various ber set out in PCT Ar otides recited in classed to	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o
1998, pages 69-76). The instant invention XIAP. WO 98/35693 disclose antisense oligonucleotides which one would use the oligonucleotides. Claims 3, 4, and 16-20 meet the criteria suggest the specific antisense oligonucleotreating disease with antisense	on comprises variou targeted to XIAP for the various ber set out in PCT Ar otides recited in classed to	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o
1998, pages 69-76). The instant invention XIAP. WO 98/35693 disclose antisense oligonucleotides which one would use the oligonucleotides. Claims 3, 4, and 16-20 meet the criteria suggest the specific antisense oligonucleotreating disease with antisense	on comprises variou targeted to XIAP for the various ber set out in PCT Ar otides recited in classed to	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o
1998, pages 69-76). The instant invention XIAP. WO 98/35693 disclose antisense oligonucleotides which one would use the oligonucleotides. Claims 3, 4, and 16-20 meet the criteria suggest the specific antisense oligonucleotreating disease with antisense	on comprises variou targeted to XIAP for the various ber set out in PCT Ar otides recited in classed to	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o
1998, pages 69-76). The instant invention XIAP. WO 98/35693 disclose antisense oligonucleotides which one would use the oligonucleotides. Claims 3, 4, and 16-20 meet the criteria suggest the specific antisense oligonucleotreating disease with antisense	on comprises variou targeted to XIAP for the various ber set out in PCT Ar otides recited in classed to	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o
1998, pages 69-76). The instant invention XIAP. WO 98/35693 disclose antisense oligonucleotides which one would use the oligonucleotides. Claims 3, 4, and 16-20 meet the criteria suggest the specific antisense oligonucleotreating disease with antisense	on comprises variou targeted to XIAP for the various ber set out in PCT Ar otides recited in classectides targeted to	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o
1998, pages 69-76). The instant invention XIAP. WO 98/35693 disclose antisense oligonucleotides which one would use the oligonucleotides. Claims 3, 4, and 16-20 meet the criteria suggest the specific antisense oligonucleotreating disease with antisense	on comprises variou targeted to XIAP for the various ber set out in PCT Ar otides recited in classectides targeted to	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o
1998, pages 69-76). The instant invention XIAP. WO 98/35693 disclose antisense oligonucleotides which one would use the oligonucleotides. Claims 3, 4, and 16-20 meet the criteria suggest the specific antisense oligonucleotreating disease with antisense	on comprises variou targeted to XIAP for the various ber set out in PCT Ar otides recited in classectides targeted to	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o
1998, pages 69-76). The instant invention XIAP. WO 98/35693 disclose antisense oligonucleotides which one would use the oligonucleotides. Claims 3, 4, and 16-20 meet the criteria suggest the specific antisense oligonucleotreating disease with antisense	on comprises variou targeted to XIAP for the various ber set out in PCT Ar otides recited in classectides targeted to	s chemical modifications to antisense Cook discloses various modifications selfits recognized in the art for such ticle 33(2)-(4), because the prior art d times 3 and 4 nor does the art teach o	oligonucleotides targeted s that are used in antisen modifications to antisen oes not teach or fairly r fairy suggest methods o

International application No.

PCT/US00/00583

Sup	pleme	ental	Box
-----	-------	-------	-----

(To be used when the space in any of the preceding boxes is not sufficient)


Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below: IPC(7): C07H 21/04; A61K 48/00; C12N 15/00, 15/15/09; C12Q 1/68 and US C1.: 536/23.1, 24.1, 24.5; 435/6, 375, 377, 455; 514/44

Form PCT/IPEA/409 (Supplemental Box) (July 1998)*





To:

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION CONCERNING SUBMISSION OR TRANSMITTAL OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

LICATA, Jane, Massey Law Offices of Jane Massey Licata 66 E. Main Street Marlton, NJ 08053

ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 07 April 2000 (07.04.00)	
Applicant's or agent's file reference RTSP-0048	IMPORTANT NOTIFICATION
International application No. PCT/US00/00583	International filing date (day/month/year) 10 January 2000 (10.01.00)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 09 September 1999 (09.09.99)

- The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the
 International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise
 indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority
 document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- 2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.
- 3. An asterisk(*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- 4. The letters "NR" appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date

Priority application No.

Country or regional Office or PCT receiving Office

Date of receipt of priority document

09 Sept 1999 (09.09.99)

09/392,580

US

28 Marc 2000 (28.03.00)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Tessadel PAMPLIEGA Tolk

ich pag

Facsimile No. (41-22) 740.14.35

Telephone No. (41-22) 338.83.38

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To: JANE MASSEY LICATA LICATA & TYRRELL 66 E. MAIN STREET MARLTON NJ 03055

Docket System Status Report Docket Book

WRITTEN OPINION

(PCT Rule 66)

- *************************************	,			
91	12/01 WO			
'1		Date of Mailing (day/month/year)	12 JUL 2001	
Applicant's or agent's file reference		REPLY DUE	vithin TWO months	
RTSP-0048		fi	rom the above date of mailing	
International application No.	International filing date	(day/month/year)	Priority date (day/month/year)	
PCT/US00/00583	10 JANUARY 2000	•	09 SEPTEMBER 1999	
International Patent Classification (IPC) Please See Supplemental Sheet.	or both national classific	cation and IPC		
Applicant ISIS PHARMACEUTICALS, INC.				

1. This writter	opinion is the first (first, etc.) drawn by this International Preliminary Examining Authority.
2. This opinion	n contains indications relating to the following items:
I X	Basis of the opinion
11	Priority
111 E	Non-establishment of opinion with regard to novelty, inventive step or industrial applicability
IV	Lack of unity of invention
v x	Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
vi	Certain documents cited
VII	Certain defects in the international application
VIII	Certain observations on the international application
3. The applica	nt is hereby invited to reply to this opinion.
When?	See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).
How?	By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.5. For the form and the language of the amendments, see Rules 66.8 and 66.9.
Also	For an additional opportunity to submit amendments, see Rule 66.4. For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.
If no reply	For an informal communication with the examiner, see Rule 66.6. y is filed, the international preliminary examination report will be established on the basis of this opinion.
4. The final de examination	ate by which the international preliminary in report must be established according to Rule 69.2 is: 09 JANUARY 2002

Name and mailing address of the IPEA/US

Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231

Facsimile No. (703) 305-3230

MCGARRY

Telephone No. (703) 308-0196

Form PCT/IPEA/408 (cover sheet) (July 1998)★

WRITTEN OPINION

International application No.

I. B	asis of the opi	nion				
1. With	regard to the ek	ements of the internal	tional application	on:*		
\mathbf{x}	-	nal application as				
	the description					
X	pages		·			as originally filed
	pages	NONE				led with the demand
	pages	NONE		, filed with the letter of		
x	the claims:	90 93				
	pages	82 and 83			***	, as originally filed
	pages	NONE NONE		, as amended (together v	•	-
	pages		filed wi	ith the letter of	, , in	ed with the demand
	pages	NONE	, llicu wi	un une retter or		
x	the drawings:			•		
لشا	pages	NONE				as originally filed
	pages	NONE				
	pages	NONE		, filed with the letter of _		
				,		
X		isting part of the de)
				·		
	pages	NONE		, filed with the letter of _		
		-		nal application (under Rule ourposes of international prelim		n (under Rules 55.2 and/
3. With	h regard to any r	nucleotide and/or a of the sequence listi		ruence disclosed in the internati	tional application,	the written opinion was
X	contained in th	he international ap	oplication in	printed form.		
		-	-	on in computer readable fo	rm.	
H	•	sequently to this A		•		
님				omputer readable form.		
		•	•	•	not so beyond (the disalogues in the
	international ar	mat the subsequent pplication as filed h	nas been furni	written sequence listing does ished.	not go beyond i	he disclosure in the
	The statement the been furnished.	hat the information	recorded in co	omputer readable form is ident	tical to the writen	sequence listing has
4. X	The amendme	ents have resulted	in the cancel	lation of:		
_		ription, pages	NONE			
		ms, Nos.	NONE			
		vings, sheets/fig_				
5.		_		mendments had not been mad	le. since they have	heen considered to go
نــا ``				Supplemental Box (Rule 70.2		, 00111 1011111111111111111111111111111
-	acement sheets w is opinion as "ori		shed to the rec	eiving Office in response to an	invitation under Ar	rticle 14 are referred to

WRITTEN OPINION

International application No.

Inventive Step (IS) Claims S. 4, and 16-20 Claims Industrial Applicability (IA) Claims Claims Claims 1-20 NONE Claims Claims 1 and 2 lack novelty under PCT Article 35(2) as being anticipated by WO 98/35693 (UNIVERSITY OF OTTOW. WO 98/35693 discloses nucleic acid sequences encoding XIAP, which is equivalent to the instant X-linked inhibit of apoptosis, and disclose, at pages 13 and 14 for example, regions of such a nucleic acid targetable by antisense and preferr antisense lengths such as 8-25 nucleotides. Example 9 and page 45 disclose that antisense to XIAP have been made and test Claims 5-15 lack an inventive step under PCT Article 35(3) as being obvious over the prior art as applied in the immediate preceding paragraph and further in view of Cook S.T. (Antisense Medicinal Chemistry. In: Antisense Research and Application 1998, pages 69-76). The instant invention comprises various chemical modifications to antisense oligonucleotides targeted to XIAP. Cook discloses various modifications that are used in antisen oligonucleotides which one would use for the various benefits recognized in the art for such modifications to antisen oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the specific antisense oligonucleotides recited in claims 3 and 4 nor does the art teach or fairly suggest methods of treating disease with antisense oligonucleotides targeted to X-linked Inhibitor of Apoptosis (XIAP).	statement			
Inventive Step (IS) Claims 1, 2, and 16-20 Industrial Applicability (IA) Claims Claims Claims 1-20 NONE Claims NONE Claims NONE Claims Claims Claims Claims NONE Claims Claims Claims NONE Claims Claim	Novelty (N)	Claims	3-20	YI
Industrial Applicability (IA) Claims		Claims	1 and 2	NO
Industrial Applicability (IA) Claims 1-20 Claims NONE Claims Claims Industrial Applicability (IA) Claims NONE Claims Claims Industrial Applicability (IA) Claims Claims Industrial Applicability (IA) Indus	Inventive Step (IS)	Claims	3, 4, and 16-20	YI.
Claims NONE Claims NONE Claims 1 and 2 lack novelty under PCT Article 55(2) as being anticipated by WO 98/55695 (UNIVERSITY OF OTTOW. WO 98/55695 discloses nucleic acid sequences encoding XIAP, which is equivalent to the instant X-linked inhibit of apoptosis, and disclose, at pages 15 and 14 for example, regions of such a nucleic acid targetable by antisense and preferr antisense lengths such as 8-25 nucleotides. Example 9 and page 45 disclose that antisense to XIAP have been made and test Claims 5-15 lack an inventive step under PCT Article 35(3) as being obvious over the prior art as applied in the immediate preceding paragraph and further in view of Cook S.T. (Antisense Medicinal Chemistry. In: Antisense Research and Application 1998, pages 69-76). The instant invention comprises various chemical modifications to antisense oligonucleotides targeted XIAP. WO 98/55693 disclose antisense targeted to XIAP. Cook discloses various modifications that are used in antisen oligonucleotides which one would use for the various benefits recognized in the art for such modifications to antisen oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set out in PCT Article 53(2)-(4), because the prior art does not teach or fairly suggest the specific antisense oligonucleotides recited in claims 3 and 4 nor does the art teach or fairy suggest methods of treating disease with antisense oligonucleotides targeted to X-linked Inhibitor of Apoptosis (XIAP).	• • •	Claims	1, 9, and 5-15	NO
Claims NONE Citations and explanations Claims 1 and 2 lack novelty under PCT Article 55(2) as being anticipated by WO 98/35693 (UNIVERSITY OF OTTOW. WO 98/35693 discloses nucleic acid sequences encoding XIAP, which is equivalent to the instant X-linked inhibit of apoptosis, and disclose, at pages 13 and 14 for example, regions of such a nucleic acid targetable by antisense and preferr antisense lengths such as 8-25 nucleotides. Example 9 and page 45 disclose that antisense to XIAP have been made and test Claims 5-15 lack an inventive step under PCT Article 33(3) as being obvious over the prior art as applied in the immediate preceding paragraph and further in view of Cook S.T. (Antisense Medicinal Chemistry. In: Antisense Research and Applications 1998, pages 69-76). The instant invention comprises various chemical modifications to antisense oligonucleotides targeted XIAP. WO 98/35693 disclose antisense targeted to XIAP. Cook discloses various modifications that are used in antisen oligonucleotides which one would use for the various benefits recognized in the art for such modifications to antisen oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the specific antisense oligonucleotides recited in claims 3 and 4 nor does the art teach or fairy suggest methods of treating disease with antisense oligonucleotides targeted to X-linked Inhibitor of Apoptosis (XIAP).	Industrial Applicability (IA)	Claims	1-20	YE
Claims 1 and 2 lack novelty under PCT Article 33(2) as being anticipated by WO 98/35693 (UNIVERSITY OF OTTOW. WO 98/35693 discloses nucleic acid sequences encoding XIAP, which is equivalent to the instant X-linked inhibit of apoptosis, and disclose, at pages 13 and 14 for example, regions of such a nucleic acid targetable by antisense and preferr antisense lengths such as 8-25 nucleotides. Example 9 and page 45 disclose that antisense to XIAP have been made and test Claims 5-15 lack an inventive step under PCT Article 35(3) as being obvious over the prior art as applied in the immediate preceding paragraph and further in view of Cook S.T. (Antisense Medicinal Chemistry. In: Antisense Research and Application 1998, pages 69-76). The instant invention comprises various chemical modifications to antisense oligonucleotides targeted XIAP. WO 98/35693 disclose antisense targeted to XIAP. Cook discloses various modifications that are used in antisen oligonucleotides which one would use for the various benefits recognized in the art for such modifications to antisen oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the specific antisense oligonucleotides recited in claims 3 and 4 nor does the art teach or fairy suggest methods of treating disease with antisense oligonucleotides targeted to X-linked Inhibitor of Apoptosis (XIAP).	, (,	Claims	NONE	NO
Claims 1 and 2 lack novelty under PCT Article \$3(2) as being anticipated by WO 98/35693 (UNIVERSITY OF OTTOW. WO 98/35693 discloses nucleic acid sequences encoding XIAP, which is equivalent to the instant X-linked inhibit of apoptosis, and disclose, at pages 13 and 14 for example, regions of such a nucleic acid targetable by antisense and preferrantisense lengths such as 8-25 nucleotides. Example 9 and page 45 disclose that antisense to XIAP have been made and test Claims 5-15 lack an inventive step under PCT Article 33(3) as being obvious over the prior art as applied in the immediate preceding paragraph and further in view of Cook S.T. (Antisense Medicinal Chemistry. In: Antisense Research and Application 1998, pages 69-76). The instant invention comprises various chemical modifications to antisense oligonucleotides targeted XIAP. WO 98/35693 disclose antisense targeted to XIAP. Cook discloses various modifications that are used in antisen oligonucleotides which one would use for the various benefits recognized in the art for such modifications to antisense oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the specific antisense oligonucleotides recited in claims 3 and 4 nor does the art teach or fairy suggest methods of treating disease with antisense oligonucleotides targeted to X-linked Inhibitor of Apoptosis (XIAP).	citations and explanations			
of apoptosis, and disclose, at pages 13 and 14 for example, regions of such a nucleic acid targetable by antisense and preferr antisense lengths such as 8-25 nucleotides. Example 9 and page 45 disclose that antisense to XIAP have been made and test Claims 5-15 lack an inventive step under PCT Article 35(3) as being obvious over the prior art as applied in the immediate preceding paragraph and further in view of Cook S.T. (Antisense Medicinal Chemistry. In: Antisense Research and Application 1998, pages 69-76). The instant invention comprises various chemical modifications to antisense oligonucleotides targeted XIAP. WO 98/55693 disclose antisense targeted to XIAP. Cook discloses various modifications that are used in antisen oligonucleotides which one would use for the various benefits recognized in the art for such modifications to antisen oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the specific antisense oligonucleotides recited in claims 3 and 4 nor does the art teach or fairy suggest methods of treating disease with antisense oligonucleotides targeted to X-linked Inhibitor of Apoptosis (XIAP).	-	cle 33(2) as bein	g anticipated by WO 98/85693 (UNIV	ERSITY OF OTTOWA)
1998, pages 69-76). The instant invention comprises various chemical modifications to antisense oligonucleotides targeted XIAP. WO 98/55695 disclose antisense targeted to XIAP. Cook discloses various modifications that are used in antisen oligonucleotides which one would use for the various benefits recognized in the art for such modifications to antisen oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the specific antisense oligonucleotides recited in claims 3 and 4 nor does the art teach or fairy suggest methods of treating disease with antisense oligonucleotides targeted to X-linked Inhibitor of Apoptosis (XIAP).	antisense lengths such as 8-25 nucleotides. En Claims 5-15 lack an inventive step under PC	kample 9 and pa T Article 33(3)	ge 45 disclose that antisense to XIAP	have been made and tested applied in the immediately
Claims 3, 4, and 16-20 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the specific antisense oligonucleotides recited in claims 3 and 4 nor does the art teach or fairy suggest methods of treating disease with antisense oligonucleotides targeted to X-linked Inhibitor of Apoptosis (XIAP). NEW CITATIONS	1998, pages 69-76). The instant invention co	mprises various	chemical modifications to antisense o	ligonucleotides targeted to
suggest the specific antisense oligonucleotides recited in claims 3 and 4 nor does the art teach or fairy suggest methods of treating disease with antisense oligonucleotides targeted to X-linked Inhibitor of Apoptosis (XIAP).	oligonucleotides which one would use for t	_		
		_		
	oligonucleotides which one would use for to oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisense es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for to oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide.	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisense es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for to oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide.	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisense es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for to oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisense es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for to oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisens es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for to oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisense es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for tooligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisens es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for tooligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisens es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for tooligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisens es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for tooligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisens es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for tooligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisens es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for to oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisens es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for to oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisens es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for to oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisens es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for to oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisens es not teach or fairly fairy suggest methods of
	oligonucleotides which one would use for tooligonucleotides. Claims 3, 4, and 16-20 meet the criteria set of suggest the specific antisense oligonucleotide treating disease with antisense oligonucleotide. NEW CITATIONS	he various ben out in PCT Art is recited in clai	efits recognized in the art for such and the such art for such art for such art does are such art does and 4 nor does the art teach or	modifications to antisen es not teach or fairly fairy suggest methods o

WRITTEN OPINION

International application No.

pported by the des	ations on the clari cription, are made	ty of the claims, descrip	tion, and drawings or	on the question whet	her the claims are full
		,			
					•

0

WRITTEN OPINION

International application No.

PCT/US00/00583

Sunt	lemen	tal	Box
JUUL	TCTI CII	Lau	DUA

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

TIME LIMIT:

The time limit set for response to a Written Opinion may not be extended. 37 CFR 1.484(d). Any response received after the expiration of the time limit set in the Written Opinion will not be considered in preparing the International Preliminary Examination Report.

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below: IPC(7): C07H 21/04; A61K 48/00; C12N 15/00, 15/15/09; C12Q 1/68 and US Cl.: 536/23.1, 24.1, 24.5; 435/6, 375, 377, 455; 514/44

INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/00583

IPC(7) : C0 US CL :536.	FICATION OF SUBJECT MATTER 7H 21/04; A61K 48/00; C12N 15/00, 15/15/0 /23.1, 24.1, 24.5; 435/6, 375, 377, 455; 514/	44	<u> </u>		
According to Int	ternational Patent Classification (IPC) or to bot	h national classification and IPC			
	SEARCHED				
	nentation searched (classification system follow				
	23.1, 24.1, 24.5; 435/6, 375, 377, 455; 514/4				
Documentation s NONE	earched other than minimum documentation to the	e extent that such documents are included	in the fields searched		
	pase consulted during the international search (in Line BIOSIS, EMBASE, CAPLUS, SCISEAR		t, search terms used)		
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.		
X W	O 98/35693 A2(UNIVERSITY OF ges 13-14, 45 and Example 9.	OTTOWA) 20 August 1998,	1, 2		
Y	Boo 10 1., 10 mile		5-15		
Re	COOK S.T. Antisense Medicinal Chemistry. In: Antisense Research and Application. Edited by Stanley Crooke. New York: Springer. 1998, pages 69-76, entire document.				
Further do	cuments are listed in the continuation of Box (See patent family annex.			
"A" document	stegories of cited documents: defining the general state of the art which is not considered stricular relevance	*T* later document published after the inte- date and not in conflict with the appli the principle or theory underlying the	cation but cited to understand		
"E" earlier doc	rument published on or after the international filing date which may throw doubts on priority claim(s) or which is	"X" document of particular relevance; the considered novel or cannot be consider when the document is taken alone	claimed invention cannot be ed to involve an inventive step		
special rea	cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art				
	published prior to the international filing date but later than y date claimed	*A.* document member of the same patent			
Date of the actual	completion of the international search	Date of mailing of the international sea 2.9 MAR 2000	rch report		
Commissioner of Box PCT	g address of the ISA/US Patents and Trademarks	Authorized officer SEAN MCGARRY	B.		
Washington, D.C. Facsimile No.	. 20231 (703) 305-3230	Telephone No. (703) 308-0196	K~		

PCT

REC'D 3 0 OCT 2001

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

PCT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference			
RTSP-0048	FOR FURTHER ACTION	See Notifi Prelimina PCT/IPEA	ication of Transmittal of International ary Examination Report (Form
International application No.	International filing date (day)	month/year)	Priority date (day/month/year)
PCT/US00/00583	10 JANUARY 2000		09 SEPTEMBER 1999
International Patent Classification (IPC Please See Supplemental Sheet.	or national classification and I	PC	
Applicant ISIS PHARMACEUTICALS, INC.			
2. This REPORT consists of a This report is also accombeen amended and are th (see Rule 70.16 and Section	total of sheets. panied by ANNEXES, i.e., sheet basis for this report and/or sheet basis for the Administrative I	according to ets of the desceets containin	ription, claims and/or drawings which have
These annexes consist of a to	tal of sheets.		
3. This report contains indication I X Basis of the report II Priority	_	ems:	
-			
III Non-establishmer	nt of report with regard to no	velty, inventi	ve step or industrial applicability
IV Lack of unity of	invention		
V X Reasoned statemen citations and explan	t under Article 35(2) with rega nations supporting such stateme	rd to novelty, ent	inventive step or industrial applicability;
VI Certain documents of	eited		
VII Certain defects in the	ne international application		
VIII Certain observations	s on the international applicati	on	
Date of submission of the demand	Date	of completion	of this report
05 APRIL 2001	01	OCTOBER 2	2001
Name and mailing address of the IPEA/	US Autho	iged officer	Rudges /
Commissioner of Patents and Tradems Box PCT Washington, D.C. 20231	urks K	AREN LACOU	JRCIERE TO
Facsimile No. (703) 305-3250	Telepl	none No. (70	03) 308-0196
Form PCT/IDEA /400 /			

International	application	No.
inite i nationai	application	1 110

I. B	asis o	f the report		
1 Witl	h regar	d to the elements of the intern	ational application:*	
x		nternational application as		
	I	description:	2 ,	
X		es1-81		, as originally filed
	page	s NONE		
			, filed with the letter of	
	41	.1		
X		claims: 82 and 83		, as originally filed
		·	, as amended (together with any	
		s NONE	, (g	
		s NONE	, filed with the letter of	
_				
X		drawings: NONE		
				, as originally filed
		·	, filed with the letter of	, filed with the demand
	Pugu		, , , , , , , , , , , , , , , , , , , ,	
X		equence listing part of the		
	page	s <u>NONE</u>	, filed with the letter of	
	the la	anguage of publication of anguage of the translation fun	the international application (under Rule 48.3(b)) mished for the purposes of international preliminary ex).
	th rega	ard to any nucleotide and/o	r amino acid sequence disclosed in the international out on the basis of the sequence listing:	al application, the international
X	conta	nined in the international a	pplication in printed form.	
\Box			onal application in computer readable form.	
片		shed subsequently to this		
			Authority in computer readable form.	
H		- · ·	ntly furnished written sequence listing does not go	beyond the disclosure in the
	inten	national application as filed	has been furnished.	
		statement that the information furnished.	recorded in computer readable form is identical to the	ne writen sequence listing has
4. X	The	amendments have resulted	in the cancellation of:	
	X	the description, pages	NONE	
	X	the claims, Nos.	NONE	
	\mathbf{x}	the drawings, sheets/fig	NONE	
5.	This		some of) the amendments had not been made, since the	ey have been considered to go
in t	laceme	nt sheets which have been furr port as "originally filed" and	indicated in the Supplemental Box (Rule 70.2(c)).** uished to the receiving Office in response to an invitation are not annexed to this report since they do not cor	under Article 14 are referred to ntain amendments (Rules 70.16
			h amendments must be referred to under item 1 and	annexed to this report.



International application No.

statement			
Novelty (N)	Claims	3-20	YE
	Claims	1 and 2	NC
Inventive Step (IS)	Claims	3, 4, and 16-20	YE
michael dup (15)	Claims	1, 2, and 5-15	NO
Industrial Applicability (IA)	Claims	1-20	YE
	Claims	NONE	NO
preceding paragraph and further in view of C	T Article 33(3) ook S.T. (Antise	as being obvious over the prior art as applied in the inse Medicinal Chemistry. In: Antisense Research and as chemical modifications to antisense oligonucleotides	mmediatel Application
preceding paragraph and further in view of C 1998, pages 69-76). The instant invention of XIAP. WO 98/35693 disclose antisense tar oligonucleotides which one would use for oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set	T Article 33(3) look S.T. (Antise omprises variou regeted to XIAP the various ber out in PCT Ar es recited in cla	as being obvious over the prior art as applied in the inse Medicinal Chemistry. In: Antisense Research and a schemical modifications to antisense oligonucleotides. Cook discloses various modifications that are used in the art for such modifications to the series of th	mmediately Application targeted to n antisens o antisens
preceding paragraph and further in view of C 1998, pages 69-76). The instant invention of XIAP. WO 98/35693 disclose antisense tar oligonucleotides which one would use for oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set suggest the specific antisense oligonucleotid	T Article 33(3) cook S.T. (Antise comprises variou geted to XIAP the various ber out in PCT Ar es recited in cla des targeted to	as being obvious over the prior art as applied in the inse Medicinal Chemistry. In: Antisense Research and a schemical modifications to antisense oligonucleotides. Cook discloses various modifications that are used in the art for such modifications to the series of th	Application targeted to n antisense o antisense
preceding paragraph and further in view of C 1998, pages 69-76). The instant invention of XIAP. WO 98/35693 disclose antisense tar oligonucleotides which one would use for oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set suggest the specific antisense oligonucleotid treating disease with antisense oligonucleotid.	T Article 33(3) cook S.T. (Antise comprises variou geted to XIAP the various ber out in PCT Ar es recited in cla des targeted to	as being obvious over the prior art as applied in the inse Medicinal Chemistry. In: Antisense Research and a schemical modifications to antisense oligonucleotides. Cook discloses various modifications that are used in the art for such modifications to the series of th	mmediately Application targeted to n antisens o antisens
preceding paragraph and further in view of C 1998, pages 69-76). The instant invention of XIAP. WO 98/35693 disclose antisense tar oligonucleotides which one would use for oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set suggest the specific antisense oligonucleotid treating disease with antisense oligonucleotid.	T Article 33(3) cook S.T. (Antise comprises variou geted to XIAP the various ber out in PCT Ar es recited in cla des targeted to	as being obvious over the prior art as applied in the inse Medicinal Chemistry. In: Antisense Research and a schemical modifications to antisense oligonucleotides. Cook discloses various modifications that are used in the art for such modifications to the series of th	mmediately Application targeted to n antisens o antisens
preceding paragraph and further in view of C 1998, pages 69-76). The instant invention of XIAP. WO 98/35693 disclose antisense tar oligonucleotides which one would use for oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set suggest the specific antisense oligonucleotid treating disease with antisense oligonucleotid.	T Article 33(3) cook S.T. (Antise comprises variou geted to XIAP the various ber out in PCT Ar es recited in cla des targeted to	as being obvious over the prior art as applied in the inse Medicinal Chemistry. In: Antisense Research and a schemical modifications to antisense oligonucleotides. Cook discloses various modifications that are used in the art for such modifications to the series of th	mmediatel Application targeted t n antisens o antisens
preceding paragraph and further in view of C 1998, pages 69-76). The instant invention c XIAP. WO 98/35693 disclose antisense tar oligonucleotides which one would use for oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set suggest the specific antisense oligonucleotid treating disease with antisense oligonucleotid.	T Article 33(3) cook S.T. (Antise comprises variou geted to XIAP the various ber out in PCT Ar es recited in cla des targeted to	as being obvious over the prior art as applied in the inse Medicinal Chemistry. In: Antisense Research and a schemical modifications to antisense oligonucleotides. Cook discloses various modifications that are used in the art for such modifications to the series of th	mmediatel Application targeted t n antisens o antisens
preceding paragraph and further in view of C 1998, pages 69-76). The instant invention c XIAP. WO 98/35693 disclose antisense tar oligonucleotides which one would use for oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set suggest the specific antisense oligonucleotid treating disease with antisense oligonucleotid.	T Article 33(3) cook S.T. (Antise comprises variou geted to XIAP the various ber out in PCT Ar es recited in cla des targeted to	as being obvious over the prior art as applied in the inse Medicinal Chemistry. In: Antisense Research and a schemical modifications to antisense oligonucleotides. Cook discloses various modifications that are used in the art for such modifications to the series of th	mmediatel Application targeted t n antisens o antisens
preceding paragraph and further in view of C 1998, pages 69-76). The instant invention of XIAP. WO 98/35693 disclose antisense tar oligonucleotides which one would use for oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set suggest the specific antisense oligonucleotid treating disease with antisense oligonucleotid.	T Article 33(3) cook S.T. (Antise comprises variou geted to XIAP the various ber out in PCT Ar es recited in cla des targeted to	as being obvious over the prior art as applied in the inse Medicinal Chemistry. In: Antisense Research and a schemical modifications to antisense oligonucleotides. Cook discloses various modifications that are used in the art for such modifications to the series of th	mmediatel Application targeted t n antisens o antisens
preceding paragraph and further in view of C 1998, pages 69-76). The instant invention of XIAP. WO 98/35693 disclose antisense tar oligonucleotides which one would use for oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set suggest the specific antisense oligonucleotid treating disease with antisense oligonucleotid.	T Article 33(3) cook S.T. (Antise comprises variou geted to XIAP the various ber out in PCT Ar es recited in cla des targeted to	as being obvious over the prior art as applied in the inse Medicinal Chemistry. In: Antisense Research and a schemical modifications to antisense oligonucleotides. Cook discloses various modifications that are used in the art for such modifications to the series of th	mmediatel Application targeted t n antisens o antisens
preceding paragraph and further in view of C 1998, pages 69-76). The instant invention of XIAP. WO 98/35693 disclose antisense tar oligonucleotides which one would use for oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set suggest the specific antisense oligonucleotid treating disease with antisense oligonucleotid.	T Article 33(3) cook S.T. (Antise comprises variou geted to XIAP the various ber out in PCT Ar es recited in cla des targeted to	as being obvious over the prior art as applied in the inse Medicinal Chemistry. In: Antisense Research and a schemical modifications to antisense oligonucleotides. Cook discloses various modifications that are used in the art for such modifications to the series of th	mmediatel Application targeted t n antisens o antisens
preceding paragraph and further in view of C 1998, pages 69-76). The instant invention of XIAP. WO 98/35693 disclose antisense tar oligonucleotides which one would use for oligonucleotides. Claims 3, 4, and 16-20 meet the criteria set suggest the specific antisense oligonucleotid treating disease with antisense oligonucleotid.	T Article 33(3) cook S.T. (Antise comprises variou geted to XIAP the various ber out in PCT Ar es recited in cla des targeted to	as being obvious over the prior art as applied in the inse Medicinal Chemistry. In: Antisense Research and a schemical modifications to antisense oligonucleotides. Cook discloses various modifications that are used in the art for such modifications to the series of th	mmediatel Application targeted t n antisens o antisens



International application No.

PCT/US00/00583

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Shee

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below: IPC(7): C07H 21/04; A61K 48/00; C12N 15/00, 15/15/09; C12Q 1/68 and US C1.: 536/23.1, 24.1, 24.5; 435/6, 37 455; 514/44